+++
CHAPTER SUMMARY AND CENTRAL ILLUSTRATION
++
Content Update
OCEANIC-AF Trial Review
The OCEANIC-AF investigators evaluated whether the oral anticoagulant asundexian, a direct and selective activated factor XI (XIa) inhibitor, would prevent strokes with anticipated less bleeding in patients with atrial fibrillation (AF). Read More
++
Content Update
EPIC-CAD Trial Review
The EPIC-CAD trial assessed long-term antithrombotic treatments in atrial fibrillation patients with stable coronary artery disease across 18 South Korean centers. Read More
++
Content Update
ARTESIA: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation
Subclinical atrial fibrillation (AF) is defined by short-lasting, asymptomatic episodes, often discovered on long-term, continuous monitoring with pacemakers or defibrillators. Read More
++
Content Update
A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab Compared With Open-Label Rivaroxaban in Patients With Atrial Fibrillation - AZALEA-TIMI 71
Abelacimab is a novel monoclonal antibody to factor XI, a key component of the intrinsic clotting pathway. Read More
++
Content Update
ADVENT trial: Pulsed field ablation for paroxysmal atrial fibrillation
The randomized, multicenter, single-blind, non-inferiority ADVENT trial compared catheter-based pulsed field ablation (PFA) to conventional thermal ablation (radiofrequency or cryoballoon) in paroxysmal atrial fibrillation. Read More
++
Content Update
CASTLE-HTx Trial: Atrial Fibrillation Ablation in End-Stage Heart Failure
Prior trials of atrial fibrillation (AF) ablation in patients with heart failure with reduced ejection fraction excluded the end-stage heart failure population. Read More
++
Content Update
Assessing the Utility of Colchicine to Prevent Atrial Fibrillation After Thoracic Surgery
The COP-AF trial was a randomized, triple-blinded, multinational trial studying the effect of oral colchicine 0.5 mg twice daily compared to matching placebo in patients 55 years and older undergoing major non-cardiac thoracic surgery. Read More
++
Content Update
DANCAVAS: Five-Year Outcomes of the Danish Cardiovascular Screening Trial
The DANCAVAS (Danish Cardiovascular Screening) trial was designed to assess the impact of population-based cardiovascular health screening with respect to the risk of death. Read More
++
Content Update
Rivaroxaban in Rheumatic Heart Disease Associated Atrial Fibrillation: The INVICTUS trial
INVICTUS was a multinational, randomized, controlled trial comparing standard dose rixaroxaban with a dose-adjusted vitamin K antagonist in patients with atrial fibrillation and echocardiographically diagnosed rheumatic heart disease. Read More
++
Chapter Summary
This chapter discusses the epidemiology, pathophysiology, and classification of atrial fibrillation (AF) and atrial flutter, as well as the clinical presentation, evaluation, and management of patients with these arrhythmias (see Fuster and Hurst’s Central Illustration). Patients may have a range of presentations from asymptomatic, with the arrhythmia detected only by electrocardiography or other monitoring, to highly symptomatic. Management approaches should be individualized to patient symptoms and comorbidities. Management of AF may require cardioversion acutely for symptomatic patients, followed by strategies to prevent recurrent AF and minimize sequelae such as stroke. An important consideration in the management of AF is lifestyle modification, because conditions such as sleep apnea, ...